Interview: Pfizer's Smith On Building A Gene Therapy Business

Pfizer entered the gene therapy space in 2014 and now has three programs in the clinic. Robert Smith, head of Pfizer’s gene therapy unit, spoke to Scrip about the company strategy, as well as the regulatory and reimbursement landscape.

Smith_Bob
Robert Smith heads Pfizer's gene therapy unit • Source: Pfizer

With Pfizer Inc. pivoting from seeking big M&A deals to grow to investing in internal R&D and smaller, earlier-stage transactions under new CEO Albert Bourla, its gene therapy unit is looking increasingly interesting as a crucible for innovation and potential growth.

The strategy has most recently seen it pay €45m for an option to buy France’s Vivet Therapeutics, with its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Gene Therapies

More from Advanced Therapies